Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Ryman-Tubb T, Lothion-Roy JH, Metzler VM, Harris AE, Robinson BD, Rizvanov AA, et al. Comparative pathology of dog and human prostate cancer. Vet Med Sci. 2021.

Baquero J, Tang X-, Scognamiglio T, Gudas LJ. EZH2 Knockout in Oral Cavity Basal Epithelia Causes More Invasive Squamous Cell Carcinomas. Carcinogenesis. 2021.

Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, et al. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021;96(11):E420-E423.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study. Vaccines (Basel). 2021;9(5).

Olson LC, Lelli GJ, Patel SS, Magro CM. Conjunctival Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) in a Young Adult Male With Persistent Ptosis. J Clin Rheumatol. 2021;27(2):e53-e58.

Liu X, Su T, Hsu Y-, Yu H, Yang HS, Jiang L, et al. Rapid identification and discrimination of methicillin-resistant Staphylococcus aureus strains via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2021;35(2):e8972.

Stern ES, Siddiqui MT. Nuclear hypochromasia: Shedding light on the "lightness" of high-grade urothelial carcinoma. Diagn Cytopathol. 2021;49(9):1032-1035.

Hwang I, Uchida H, Dai Z, Li F, Sanchez T, Locasale JW, et al. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat Commun. 2021;12(1):640.

Yin Y, Zhu L, Li Q, Zhou P, Ma L. Cullin4 E3 Ubiquitin Ligases Regulate Male Gonocyte Migration, Proliferation and Blood-Testis Barrier Homeostasis. Cells. 2021;10(10).

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.